Introduction
The main constituent of senile plaques found in the brains of Alzheimer's disease (AD) patients is the amyloid ͱ peptide (Aͱ), a proteolytic cleavage product of the larger, mem-brane-bound, amyloid precursor protein (APP; 1). Aͱ is produced by various cell types and is secreted into blood and cerebrospinal fluid (CSF; 2,3). Soluble Aͱ shows variations in the N-as well as the C-termini, but the majority of the peptides end at residue 40 (Aͱ40). The amount of peptides ending at residue 42 (Aͱ42) is roughly 1/10 of the Aͱ40 peptides (4) (5) (6) . Quantification of soluble Aͱ in blood and CSF has been performed with enzyme-linked immunosorbent assays (ELISAs) (3, 5, (7) (8) (9) (10) (11) (12) (13) (14) (15) , immunoradiometric sandwich assay (16) , immunoprecipitation/blotting (17) (18) (19) or direct western blots (19) . Specific quantification of Aͱ42 in CSF by ELISA has been performed using the 277-2 antibody (10, 12) , 21F12 (14, 15) and BC-05 (5, 11, 13) . Only one antibody specific for Aͱ40, BA-27, has been described in ELISA assays quantifying soluble Aͱ in CSF (11) and in blood (5, 20) .
In the present study, we developed new, highly specific ELISA systems for quantification of Aͱ40 and Aͱ42 in CSF. The antibodies used were W0-2 for capture and G2-10 and G2-11 for Aͱ40 and Aͱ42 detection, respectively, all previously described (19) . In addition to previous studies on the antibody specificity (19) , we thoroughly investigated the specificity of the three antibodies by several methods. We performed epitope mapping, where binding of antibody to overlapping peptides synthesized on a membrane was tested [the (SPOT) synthesis method (21) ]. This method gives detailed information on linear epitopes. Peptides immunoprecipitated by the antibodies were investigated with matrix-assisted laser desorption ionization/time of flight mass spectrometry (MALDI-TOF-MS) to confirm binding of the antibodies to the cognate peptides. We examined the binding capacity of G2-11 to synthetic Aͱ1-42 in soluble or fibrillar conformation states by direct ELISA. We also investigated the abilities of the antibodies to bind synthetic Aͱ1-40 and 1-42, which were preincubated with CSF for different lengths of time to test if components in the CSF affected the immunoreactivity of the peptides. Finally, the stability of endogenous Aͱ40 and Aͱ42 in CSF was studied during different conditions to optimize the sample handling process from lumbar puncture to Aͱ assay.
Materials and Methods

Antibody Specificity Experiments
PEPTIDE SYNTHESIS AND EPITOPE MAPPING. SPOT peptide synthesis was performed according to Frank (21) . Nitrocellulose membranes were chemically derivatized with Fmoc-ͱ-alanine to provide anchor function and spacer arms. Decapeptides overlapping each other by one amino acid, covering residues 1-42 of Aͱ, were synthesized using Fmoc chemistry. Chromatography paper Chr 1 was purchased from Whatman (Kebo, Stockholm, Sweden). N-N-dimethylformamide (DMF), N-N-methylpyrrolidinone (NMP), piperidine, dichloromethane (DCM), trifluoroacetic acid (TFA), N-N-diisopropylethylamine, acetic anhydride, triisobutylsilane, N-Fmoc-ͱ-alanine, molecular sieves 4 Å, methanol, carbodiimide (DIC), NaN 3 , acetic acid, N-methyl-imidazole (NMI) and 1-hydroxybenzotriazole (Hobt) were all purchased from Fluka (Stockholm, Sweden). Fmoc amino acid derivatives were purchased from Bachem (Stockholm, Sweden) and bromophenol blue from Amersham (Uppsala, Sweden).
The antibody-binding assay was principally perfomed according to Frank (21) , but was modified in several ways. Membranes were transferred from the freezer to a glass dish on a rocking plate and rinsed twice with methanol. The following series of incubations were carried out: Tris buffered saline (TBS) containing 0.05% Tween-20 (T-TBS; 5 min), blocking buffer (5% skim milk powder in T-TBS; 10 min), first antibody (1:10000) in blocking buffer ϩ 0.05% NaN 3 (overnight), T-TBS (three times for 5 min each), horseradish peroxidase (HRP)-coupled anti-mouse antibody (1:500) (Amersham) in blocking buffer (30 min), T-TBS (five times for 20 min each), enhanced chemiluminescent protein (ECL) detection (Amersham). The epitope mappings were repeated twice for all three antibodies.
IMMUNOPRECIPITATION/MASS SPECTROMETRY. Antigen specificity of G2-10 and G2-11 was tested by immunoprecipitation-mass spectrometry (IP-MS). The antibodies were incubated with synthetic Aͱ1-40 and 1-42 and conditioned media from cells expressing human APP. Synthetic Aͱ was prepared to a final concentration of 10 nM in TBS. Immunoprecipitation was carried out by incubating 2 l of G2-10 (1 mg/ ml), 1 l of G2-11 (ascites fluid, 2-3 mg/ml) or 1 l of 6E10 (3.3 mg/ml, Senetek, Maryland Heights, MO) with 1 ml of the synthetic Aͱ solution at 4ЊC for 3 hr. Mouse neuroblastoma (N2a) cells stably transfected with wild-type human APP and presenilin1 cDNA were incubated with serum-reduced medium for 24 hr. Protease inhibitors (2 mM EDTA-Na 2 , 10 M leupeptin, 1 M pepstatin, 1 M (PMSF), 0.1 mM (TLCK) and 0.2 mM (TPCK)) were added to the conditioned media. The same amounts of antibodies, as described above, were added to 1 ml of conditioned media and incubated at 4ЊC for 3 hr. The immunoprecipitated Aͱ pep-tides were analyzed using a matrix-assisted laser desorption ionization time-of-flight mass spectrometer (MALDI-TOF-MS) (Voyager-DE STR BioSpectrometry Workstation, PerSeptive Biosystem, Farmingham, MA) as described previously (22 Synthetic Aͱ1-40 and 1-42 were solubilized to 1 mg/ml in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), aliquoted in 10 l aliquots in eppendorf tubes, incubated at room temperature (r.t.) for 30 min and stored at Ϫ70ЊC until assayed. Immediately before analyses, HFIP was removed using a spin-vacuum system. 100 l of CSF was added to each tube to resolubilize the peptide to 0.1 mg/ml, whereupon, the tubes were incubated in 25ЊC, 4ЊC, Ϫ20ЊC or Ϫ70ЊC. In each temperature, the tubes were incubated for 0, 3, 24, 168 or 336 hr before being assayed. Immediately prior to being assayed, the 0.1 mg/ml solutions of peptide in CSF or H 2 O were further diluted in coating buffer (0.1 M sodium carbonate buffer, pH 9.6) to 5 Ȑg/ml for the G2-10 assay and to 50 Ȑg/ml for the W0-2 and G2-11 assays. 100 Ȑl of the peptide solutions were added to each well on a 96-well plate and each sample was analyzed in duplicate (plates were obtained from Nunc, Denmark). The plates were incubated at 4ЊC overnight and then washed four times with phosphate-buffered saline (PBS) containing 0.05% Tween-20. Biotinylated (Sulfo-NHSbiotin, Pierce, Rockford, IL) W0-2, G2-10 and G2-11 were diluted 1:40000 in ELISA buffer [4% ELISA blocking reagent (Boehringer Mannheim, Stockholm, Sweden), 0.2% bovine serum albumin (BSA), 2% Tween-20 and 2% goat serum in PBS, pH 7.4] for the assays of Aͱ stored in H 2 O and 1:4000 for the assays of Aͱ stored in CSF. 100 Ȑl (0.5 ͨg/ml) antibody were added per well and incubated for 90 min at r.t. on a plate shaker. The plates were washed as before and HRP-conjugated streptavidine was added and incubated for 1 hr. 100 Ȑl solution [1 mg/ml ortho-phenylenediamine (Sigma, Stockholm, Sweden) in a substrate buffer containing 52 mM Na 2 4 • H 2 O in 500 ml water). Artificial CSF containing albumin was prepared by adding 0.4 mg/ml of human albumin (Sigma, Stockholm, Sweden) to the above solution.
PREPARATION OF FIBRILLAR Aͱ42 AND ELECTRON MI-CROSCOPY OF PEPTIDES. Synthetic Aͱ1-42 was dissolved in deionized water at a concentration of 1 mg/ml, vortexed and immediately frozen in liquid nitrogen. To obtain fibrillar Aͱ, vials were rapidly thawed and incubated at 37ЊC for 7 days. 5 Ȑl of Aͱ solution were placed on a carbon-coated Formvar-grid (200 mesh) and diluted with 5 Ȑl of 0.5% (v/v) glutaraldehyde solution after 2 min. The total adsorption time was 3 min. Thereafter, the grid was rinsed with deionized water, dried with a piece of filter paper and negatively stained with 5 Ȑl of 2% (w/v) uranylacetate solution for 2 min. Finally, the grid was wicked off, air-dried and examined using a Zeiss EM 10 electron microscope (Carl Zeiss, Jena, Germany).
Sandwich ELISA
Plates were coated with 100 Ȑl of W0-2 antibody in 0.1 M sodium carbonate buffer, pH 9.6. The plates were coated at 4ЊC overnight and then blocked with 100 Ȑl per well of ELISA blocking reagent (Boehringer Mannheim, Stockholm, Sweden) for 1 hr. Synthetic Aͱ1-40 and Aͱ1-42 peptides for the standard curves were dissolved at 1 mg/ml in 70% formic acid, aliquoted and frozen at Ϫ70ЊC. Immediately prior to addition of samples to the ELISA plates, the peptides were thawed, diluted 1:1000 in dH 2 O and further diluted in ELISA buffer, thus, obtaining neutral pH. Aͱ peptide solutions were added, in duplicate, at the following concentrations: 250, 125, 62.5, 31.25, 15.63 and 3.91 pM. If more than one plate were analyzed at the same time, the same batch of standard curve dilutions was used for all plates.
The ELISA buffer described above was used as dilution buffer for sample, standard curve and detection antibody. CSF samples were diluted 1:10 and 1:3 with dilution buffer for Aͱ40 and Aͱ42 assays, respectively. Samples (100 Ȑl per well) were analyzed, in duplicate. Two sample incubation conditions were evaluated, at 37ЊC for 3 hr and at 4ЊC overnight. All ELISA plates were normalized to each other by inclusion of three standard CSF samples on all plates.
Biotinylated detection antibodies G2-10 and G2-11 (100 Ȑl per well) were added at a concentration of 4.5-5 nM. Incubation times of 3 hr at 37ЊC and overnight at 4ЊC were evaluated. After binding of the biotinylated secondary antibody, streptavidin conjugated HRP (0.5 Ȑg/ml, 100 Ȑl per well) was allowed to bind for 1 hr at r.t. on a plate shaker. HRP activity was determined using orthophenylenediamine as described above.
Stability Analysis of Endogenous Aͱ in CSF
Stability of Aͱ in CSF was investigated by incubation of samples at 20ЊC and 4ЊC for 24 hr, 6 hr and 0 hr to mimic the clinical sample-handling procedure from lumbar puncture to storage of CSF before assay. The effect of repeated freezing/thawing cycles was investigated by thawing samples 5, 10 and 15 times. All samples were thawed once, aliquoted and refrozen before being subjected to the different temperature treatments, which meant that all samples were thawed at least twice. Eight groups with eight CSF samples per group were treated as described in Table 1 and analyzed with ELISA. The values for group 1 (analyzed directly after the second thawing) were used as control values.
Results
G2-10 and G2-11 Specifically Detect Aͱ40 and Aͱ42 Peptides In CSF and Cell Culture Media
In the epitope mapping experiments, G2-10 was found to react strongly with the synthetic peptides covering amino acids 30-39 and 31-40, suggesting the requirement of residues 39 or 40 for antibody recognition (Fig. 1A) . We also found a weak reaction with the synthetic 32-41 and 33-42 peptides, suggesting a weak cross-reaction with the G2-11 epitope. However, in sandwich ELISAs employing G2-10 as a detection antibody, we did not find any cross-reaction with the synthetic 1-42 peptide below 500 pM, well above the concentration range for analysis of diluted CSF ( Fig. 2A) . G2-11 reacted strongly with the 32-41 and 33-42 peptides, suggesting residues 41 or 42 in C-terminal position as the epitope for G2-11 (Fig. 1B) . In addition, sandwich ELISA with synthetic peptides confirmed the lack of crossreactivity with peptides lacking these residues (Fig. 2B) . Peptides ending at residue 43 were not tested in this epitope mapping.
The W0-2 antibody reacted with the peptides covering residues 1-10, 2-11, 3-12, and 4-13. The common motif for these peptides consisted of residues 4-10, thereby suggesting this region as the W0-2 epitope (Fig. 1C) . As peptides ending before residue 10 were not synthesized, we did not know if W0-2 would react with peptides ending at residues 5, 6, 7, 8 At these concentrations, the W0-2/G2-10 ELISA does not cross-react with Aͱ1-42 (A) and the W0-2/G2-11 ELISA does not cross-react with Aͱ1-40. or 9 and we, therefore, could not exclude that the epitope ended before residue 10.
To further establish the specificities of G2-10 and G2-11 by an additional method, IP-MS was performed. At first, synthetic Aͱ1-40 and 1-42 were immunoprecipitated with the antibodies. G2-10 showed, as indicated with the SPOTs mapping method, strong affinity for Aͱ1-40 and a slight cross-reactivity with Aͱ1-42 (Fig. 3A) , similar to the pattern found with the commercial 6E10 antibody (specific for the N-terminus of Aͱ; Fig. 3B ). G2-11 only showed immunoreactivity with the Aͱ1-42 peptide (Fig. 3C) . In conditioned media from N2a cells expressing human wild-type APP and presenilin 1, no cross-reaction of G2-10 with secreted Aͱ1-42 was found (Fig. 3D) ; whereas, 6E10 confirmed the presence of Aͱ1-42 in the media (Fig. 3E) . G2-11 specifically recognized the secreted Aͱ1-42 peptide (Fig.3F) .
G2-11 Recognized Soluble and Fibrillar Aͱ1-42 Equally Well
To analyze the immunoreactivity of G2-11 against Aͱ1-42 peptides in different states of aggregation, soluble and fibrillar Aͱ1-42 were prepared. The aggregation states of the two preparations were confirmed by electron microscopy ( Fig. 4A and B) . Using direct ELISA, we found a similar binding affinity of G2-11 for soluble and fibrillar Aͱ1-42 (Fig. 5) .
The Parameters of the ELISA Systems
Of the sample incubation times tested, the overnight incubation resulted in higher sensitivity for Aͱ40, as well as for Aͱ42. Incubation of the secondary antibodies overnight at 4ЊC gave a better result, compared with incubation for 3 hr at 37ЊC. When the assays were optimized, the ELISA systems were found to be able to quantify Aͱ40 and Aͱ42 at concentrations ranging from 20 pM up to 250 pM, which was sensitive enough to readily detect Aͱ42 and Aͱ40 in diluted human CSF. When assaying Aͱ40 and Aͱ42 in CSF, three standard CSF samples were added to each plate. The plates were normalized against each other by calculating the mean values of the standard CSF samples on all plates, followed by correction of all samples on each plate according to this mean value. The intra-assay variation was determined to 3% and 2% (coefficient of variation) and the inter-assay variation to 10% and 2% for the Aͱ42 and Aͱ40 assays, respectively.
CSF Reduces the Immunoreactivity of Synthetic Aͱ1-42 Peptide
Synthetic Aͱ1-42 peptide was incubated in CSF or H 2 O for different lengths of time and under different temperature settings, to determine if the antigenicity of the peptides would be affected differently by the storage conditions. We found that the antibody-binding capacity of peptides dissolved in CSF immediately prior to the overnight incubation in the ELISA was reduced to levels below the detection limit of the assay, even if the concentration of G2-11 was increased 10-fold for the analysis of peptide stored in CSF, compared with peptide stored in H 2 O (not shown). Next, synthetic Aͱ1-40 and 1-42 peptides were added to CSF to generate final concentrations of 100, 250 and 500 pM. In accordance with the former experiment, the Aͱ40 and 42 values measured in the samples were 25-65% of the expected levels. When synthetic peptide was diluted in artificial CSF, with and without physiological concentrations of human albumin, the solution containing albumin showed significantly lower Aͱ levels (p ϭ 0.01, paired t-test), compared with nonalbumin containing artificial CSF (Fig. 6) .
Endogenous Aͱ Immunoreactivity In CSF Decreases with Time
Before quantifying endogenous Aͱ40 and Aͱ42 in CSF, we wanted to examine the stability of Aͱ immunoreactivity in CSF to evaluate the importance of sample handling after lumbar puncture. We investigated the stability over time at 20ЊC and 4ЊC, and we also evaluated the effect of repeated freezing/thawing cycles. We found significantly reduced Aͱ40 and Aͱ42 immunoreactivity in samples that were stored at 20ЊC for 24 hr (mean decrease 8%, p ϭ 0.04 for Aͱ40 and mean decrease 10%, p ϭ 0.02 for Aͱ42) or thawed more than 15 times (mean decrease 12%, p ϭ 0.04 for Aͱ40 and mean decrease 19%, p ϭ 0.02 for Aͱ42), compared with the control values. For Aͱ42, a significant decrease was detected after 6 hr at 20ЊC (mean decrease 10%, p ϭ 0.04).
Discussion
In recent years, the Aͱ peptide has been shown to play an important role in AD pathogenesis. With this knowledge, an increased need for a reliable method to quantify Aͱ40 and Aͱ42 has arisen. Studies on the cell biological processes underlying AD pathogenesis, as well as investigations of potential biochemical diagnostic markers of the disease are dependent on reliable and specific analytical tools for Aͱ quantification. In this study, we present two sensitive ELISAs specifically measuring Aͱ40 and Aͱ42 in human CSF. We confirm the specificity of the antibodies previously reported (19) by several methods, experiments that have not been reported for other Aͱ40 and Aͱ42 ELISA assays. Results show a weak cross-reaction of the G2-10 antibody with Aͱ1-42 at high concentrations of synthetic peptide in epitope mapping and IP-MS experiments, but this cross-reaction is not present in conditioned media from cells over-expressing human APP. In addition, it is not seen at the concentrations of synthetic peptide used in ELISA standard curves for quantification of Aͱ40 in CSF and we, therefore, conclude that G2-10 specifically detects Aͱ40 in CSF. The difference in cross-reactivity between synthetic and cell-derived Aͱ might indicate a difference in the conformation of the peptides. It is also possible that components of the cell culture media might affect the ability of the antibody to recognize its epitope by masking it, as we discuss below. In the epitope mapping experiment, it is possible that the shorter length of the peptides, compared with full-length Aͱ might influence the protein folding and, thereby, the exposure of the epitope region. It was recently reported by Pitschke and colleagues (23) that a larger fraction of Aͱ in CSF is aggregated in AD, compared with controls. We, therefore, investigated whether our antibodies recognized soluble and fibrillar Aͱ differently. We are able to show that G2-11 detects synthetic Aͱ1-42 peptides of both aggregation states equally well, which suggests that our Aͱ42 ELISA quantifies all Aͱ42 peptides with equal affinity, regardless of the aggregation state. Before sandwich ELISA analysis of en- (32) and immunoglobulins (25) . Furthermore, binding of synthetic Aͱ42 peptide to several plasma proteins, which are also present in CSF, was recently found to mask the epitope for an Aͱ42-specific antibody (33) . CSF has also been shown to inhibit Aͱ fibril formation, suggesting that a CSF component binds Aͱ and, thereby, inhibits aggregation (25, 34) . In the sandwich ELISA experiment, the above findings were further investigated by another approach. CSF was "spiked" with synthetic peptide of different concentrations to test whether an increase in immunoreactivity, corresponding to the amount of synthetic peptide added, would be seen. In concordance with the previous experiment, the amount of Aͱ in the samples, as estimated by the synthetic peptide standard curve, does not correspond to the amount of synthetic Aͱ added in the samples. To analyze whether Aͱ is degraded within CSF or if Aͱ-binding proteins might affect the immunoreactivity of Aͱ, we mimicked the salt concentrations and pH of CSF in the preparation of artificial CSF with and without physiological concentrations of human albumin. The immunoreactivities of synthetic Aͱ1-40 and 1-42 are lower in the albumin-containing solution, which supports the study by Kuo and colleagues (35) , who found that binding of Aͱ42 to several proteins, including albumin, inhibited binding of an Aͱ42-specific antibody to the peptide.
Taken together, the above results suggest that it is the binding of synthetic Aͱ to CSF proteins that masks the epitopes of antibodies directed at the C terminus of Aͱ, rather than degradation of Aͱ in CSF that causes Aͱ immunoreactivity in CSF to decrease in our experiments. This protein interaction may render the determination of absolute amounts of Aͱ in CSF more difficult and should be kept in mind when this quantification is done. As our IP-MS experiments indicate, a direct comparison between synthetic and cell-derived Aͱ should be interpreted with caution.
We also investigated the stability of endogenous Aͱ40 and Aͱ42 in CSF over time to optimize the sample-handling procedures before assaying for Aͱ40 and Aͱ42. Our conclusions are that measurements of Aͱ40 and Aͱ42 in CSF give reproducible results when the CSF is stored at 20ЊC for up to 6 hr at 4Њ for at least 24 hr or thawed 2-12 times. The setup of the experiment does not allow us to analyze samples that had never been, or were only once, thawed. Therefore, we can not exclude the possibility that the first thawing affects Aͱ immunoreactivity more than the following thawings. The time limit of 6 hr is normally not exceeded during routine procedures for lumbar puncture, but our results indicate that the immunoreactivity of Aͱ in CSF does decrease over time. For the most reproducible results, samples should be kept cold and be frozen as fast as possible.
In conclusion, we present highly sensitive ELISA systems for quantification of Aͱ42 and Aͱ40 in CSF, employing very well-characterized antibodies, and identified some of the difficulties connected with the construction of such an assay. Our data on Aͱ stability in CSF might be useful as a guideline for correct treatment of samples from lumbar puncture to ELISA assay.
